ReviewNeurosurgery clinics of North America2010
Challenges in clinical design of immunotherapy trials for malignant glioma.
Review in Neurosurgery clinics of North America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 47 citations in OpenAlex.
- Recent advances in lipid and biomimetic nanocarriers for nucleic acid delivery in glioblastoma.Discover oncology · 2026Review
- LncRNA PSMB8-AS1 increases glioma malignancy via the miR-382-3p/BCAT1 axis.Translational oncology · 2024Article
- Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway.Experimental brain research · 2023Article
- Cellular Conversations in Glioblastoma Progression, Diagnosis and Treatment.Cellular and molecular neurobiology · 2023Review
- Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions.Advances in experimental medicine and biology · 2019Article
- miRNA-451 inhibits glioma cell proliferation and invasion by downregulating glucose transporter 1.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.Journal of neuro-oncology · 2016Article
- Immunotherapy in glioblastoma: emerging options in precision medicine.CNS oncology · 2016Review
- Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis.OncoTargets and therapy · 2016Article
- Regulatory T cells are not a strong predictor of survival for patients with glioblastoma.Neuro-oncology · 2015Article
- Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma.The Journal of biological chemistry · 2014Article
- Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.BioMed research international · 2014Review
- Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children.OncoTargets and therapy · 2014Article
- Assessment of genetic markers and glioblastoma stem-like cells in activation of dendritic cells.Human cell · 2013Article
- TRP-ing up brain tumors.Nature medicine · 2012Article
- Recent developments on immunotherapy for brain cancer.Expert opinion on emerging drugs · 2012Review
- Impact of temozolomide on immune response during malignant glioma chemotherapy.Clinical & developmental immunology · 2012Review
- Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.Neuro-oncology · 2011Article
- Molecular alterations in glioblastoma: potential targets for immunotherapy.Progress in molecular biology and translational science · 2011Review
- Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.Clinical & developmental immunology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma multiforme (GBM) is the most common and lethal primary malignant brain tumor. The traditional treatments for GBM, including surgery, radiation, and chemotherapy, only modestly improve patient survival. Therefore, immunotherapy has emerged as a novel therapeutic modality. Immunotherapeutic strategies exploit the immune system's ability to recognize and mount a specific response against tumor cells, but not normal cells. Current immunotherapeutic approaches for glioma can be divided into 3 categories: immune priming (active immunotherapy), immunomodulation (passive immunotherapy), and adoptive immunotherapy. Immune priming sensitizes the patient's immune cells to tumor antigens using various vaccination protocols. In the case of immunomodulation, strategies are aimed at reducing suppressive cytokines in the tumor microenvironment or using immune molecules to specifically target tumor cells. Adoptive immunotherapy involves harvesting the patient's immune cells, followed by ex vivo activation and expansion before reinfusion. This article provides an overview of the interactions between the central nervous system and the immune system, and discusses the challenges facing current immunotherapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.